0001104659-22-070184.txt : 20220610
0001104659-22-070184.hdr.sgml : 20220610
20220610164908
ACCESSION NUMBER: 0001104659-22-070184
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220609
FILED AS OF DATE: 20220610
DATE AS OF CHANGE: 20220610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BARBARI SHARON
CENTRAL INDEX KEY: 0001240499
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36464
FILM NUMBER: 221009573
MAIL ADDRESS:
STREET 1: 280 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER NAME:
FORMER CONFORMED NAME: BARBARI SHARON SURREY
DATE OF NAME CHANGE: 20030610
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGILE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001261249
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 COLLEGE ROAD EAST
STREET 2: SUITE 310
CITY: PRINCETON
STATE: NJ
ZIP: 08540-6635
BUSINESS PHONE: 609-683-1880
MAIL ADDRESS:
STREET 1: 500 COLLEGE ROAD EAST
STREET 2: SUITE 310
CITY: PRINCETON
STATE: NJ
ZIP: 08540-6635
4
1
tm2218213-7_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-06-09
0
0001261249
AGILE THERAPEUTICS INC
AGRX
0001240499
BARBARI SHARON
500 COLLEGE ROAD EAST, SUITE 310
PRINCETON
NJ
08540
1
0
0
0
Common Stock
2022-06-09
4
A
0
670
0
A
1952
D
Employee Stock Option (Right to Buy)
1.22
2022-06-09
4
A
0
807
0
A
2032-06-08
Common Stock
807
807
D
These shares represent restricted stock units that were granted on June 9, 2022, which will vest and be settled in common stock on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
On April 26, 2022, the Issuer completed a one-for-forty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split.
This option was granted on June 9, 2022 and vests in full on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
/s/ Geoffrey P. Gilmore, Attorney-in-fact
2022-06-10